Tag Archives: NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals (ORMP – Research Report), with a price target of $25. The company’s shares closed on Friday at $4.15. Selvaraju observed: “Valuation methodology, risks

Oramed Pharmaceuticals (ORMP) Gets a Hold Rating from B.Riley FBR

B.Riley FBR analyst Andrew D’silva maintained a Hold rating on Oramed Pharmaceuticals (ORMP – Research Report) yesterday and set a price target of $5. The company’s shares opened today at $3.50, close to its 52-week low of $2.97. D’silva said:

Oramed Pharmaceuticals (ORMP) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (NASDAQ: ORMP) today and set a price target of $25. The company’s shares closed yesterday at $4.70, close to its 52-week low of $4.60. Selvaraju wrote: “Valuation methodology,

H.C. Wainwright Thinks Oramed Pharmaceuticals’ Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (NASDAQ: ORMP) today and set a price target of $25. The company’s shares closed on Friday at $4.87, close to its 52-week low of $4.60. Selvaraju wrote: “Valuation

What Did This CEO Just Do with Personal Shares of Oramed Pharmaceuticals (NASDAQ: ORMP)?

Today, the President & CEO of Oramed Pharmaceuticals (NASDAQ: ORMP), Nadav Kidron, sold shares of ORMP for $364. This is Kidron’s first Sell trade following 4 Buy transactions. See today’s analyst top recommended stocks >> Currently, Oramed Pharmaceuticals has an

H.C. Wainwright Keeps Their Buy Rating on Oramed Pharmaceuticals

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (NASDAQ: ORMP) today and set a price target of $25. The company’s shares closed yesterday at $9.05. Selvaraju wrote: “Granted; Patent Estate Expanded; Reiterate Buy Stock Data 11/21/2017